Jeffrey A. Towbin – författare

Cardioskeletal Myopathies in Children and Young Adults focuses on plaques that kill people in their 40's-50's and the way they start to form in young adulthood. The Annals of Family Medicine report that approximately half of young adults have at least one cardiovascular disease risk factor (Mar 2010), and an increase in cardiovascular mortality rates in young adults was substantiated in a study at Northwestern Medicine (Nov 2011).

Given the increasing recognition of genetic triggers behind all types of cardiovascular disease, and the growing population of young adults with primary or acquired myocardial disease, the need has arisen for a reference that offers a comprehensive approach to the understanding of basic, translational, and clinical aspects of specific muscle diseases while making the link between young adult and adult health.

Reveals the link between cardiac muscle disease and skeletal muscle disease Explains how genetics and environmental factors effect muscle function of diverse origins Designates current and novel therapeutic strategies that target both cardiac and skeletal muscle systems

Cardioskeletal Myopathies in Children and Young Adults focuses on plaques that kill people in their 40''s-50''s and the way they start to form in young adulthood. The Annals of Family Medicine report that approximately half of young adults have at least one cardiovascular disease risk factor (Mar 2010), and an increase in cardiovascular mortality rates in young adults was substantiated in a study at Northwestern Medicine (Nov 2011).Given the increasing recognition of genetic triggers behind all types of cardiovascular disease, and the growing population of young adults with primary or acquired myocardial disease, the need has arisen for a reference that offers a comprehensive approach to the understanding of basic, translational, and clinical aspects of specific muscle diseases while making the link between young adult and adult health.- Reveals the link between cardiac muscle disease and skeletal muscle disease- Explains how genetics and environmental factors effect muscle function of diverse origins- Designates current and novel therapeutic strategies that target both cardiac and skeletal muscle systems

Heart Failure in the Child and Young Adult: From Bench to Bedside combines multiple etiologies for pediatric heart failure, including congenital heart disease, cardiomyopathies, infectious diseases and metabolic abnormalities. This comprehensive resource combines research from multiple contributors with current guidelines to bridge the knowledge gap for the recognition and management of heart failure in children. Coverage begins with the basic science of heart failure, then progresses through diagnosis, management, treatment and surgery, finally concluding with advanced special topics, including genetics, self-management and nanomedicine.

Provides coverage of the basic science of heart failure, its epidemiology and economic aspects, outpatient and inpatient management, and advanced therapies, including mechanical circulatory support and heart transplantation Combines cutting-edge research with current guidelines from the field

Heart Failure in the Child and Young Adult: From Bench to Bedside combines multiple etiologies for pediatric heart failure, including congenital heart disease, cardiomyopathies, infectious diseases and metabolic abnormalities. This comprehensive resource combines research from multiple contributors with current guidelines to bridge the knowledge gap for the recognition and management of heart failure in children. Coverage begins with the basic science of heart failure, then progresses through diagnosis, management, treatment and surgery, finally concluding with advanced special topics, including genetics, self-management and nanomedicine.- Provides coverage of the basic science of heart failure, its epidemiology and economic aspects, outpatient and inpatient management, and advanced therapies, including mechanical circulatory support and heart transplantation- Combines cutting-edge research with current guidelines from the field

Heart Failure in the Child and Young Adult: From Bench to Bedside, Second Edition highlights unique aspects of heart failure in the young. This comprehensive resource combines research from multiple contributors with current guidelines to bridge the knowledge gap for the recognition and management of heart failure in children. Coverage begins with the basic science of heart failure and then progresses through diagnosis, management, treatment, and surgery, finally concluding with advanced special topics, including genetics, self-management, and nanomedicine.This new edition covers advancements in the field, including additional chapters and discussion on biomarkers, neuromuscular disease, quality of life, palliative care, and the impact of COVID-19 in myocarditis and multisystem inflammatory syndrome in children. It will serve as an indispensable reference to basic science researchers in cardiology, pediatrics, cardiologists, and pediatric cardiologists. - Combines cutting-edge research with current guidelines from the field- Provides coverage of the basic science of heart failure, its epidemiology and economic aspects, outpatient and inpatient management, and advanced therapies, including mechanical circulatory support and heart transplantation- Includes expanded chapters on the immune system and inflammation in the development and progression of heart failure- Reviews new randomized controlled trials in pediatric heart failure

Heart Failure in the Child and Young Adult: From Bench to Bedside, Second Edition highlights unique aspects of heart failure in the young. This comprehensive resource combines research from multiple contributors with current guidelines to bridge the knowledge gap for the recognition and management of heart failure in children. Coverage begins with the basic science of heart failure and then progresses through diagnosis, management, treatment, and surgery, finally concluding with advanced special topics, including genetics, self-management, and nanomedicine.This new edition covers advancements in the field, including additional chapters and discussion on biomarkers, neuromuscular disease, quality of life, palliative care, and the impact of COVID-19 in myocarditis and multisystem inflammatory syndrome in children. It will serve as an indispensable reference to basic science researchers in cardiology, pediatrics, cardiologists, and pediatric cardiologists.

Combines cutting-edge research with current guidelines from the fieldProvides coverage of the basic science of heart failure, its epidemiology and economic aspects, outpatient and inpatient management, and advanced therapies, including mechanical circulatory support and heart transplantationIncludes expanded chapters on the immune system and inflammation in the development and progression of heart failureReviews new randomized controlled trials in pediatric heart failure

The molecular basis for atrial fibrillation continues to be largely unknown, and therapy remains unchanged, aimed at controlling the heart rate and preventing systemic emboli with anticoagulation. Familial atrial fibrillation is more common than previously suspected. While atrial fibrillation is commonly associated with acquired heart disease, a significant proportion of individuals have early onset without other forms of heart disease, referred to as "lone" atrial fibrillators. It is also well recognized that atrial fibrillation occurs on a reversible or functional basis, without associated structural heart disease, such as with hyperthyroidism or of atrial fibrillation following surgery. It remains to be determined what percentage in these individuals is familial or due to a genetic predisposition. Mapping the locus for familial atrial fibrillation is the first step towards the identification of the gene. Isolation of the gene and subsequent identification of the responsible molecular genetic defect should provide a point of entry into the mechanism responsible for the familial form and the common acquired forms of the disease and eventually provide more effective therapy. We know that the ionic currents responsible for the action potential of the atrium is due to multiple channel proteins as is electrical conduction throughout the atria. Analogous to the ongoing genetic studies in patients with familial long QT syndrome, it is highly likely that defects in each of these channel proteins will be manifested in familial atrial fibrillation.

The molecular basis for atrial fibrillation continues to be largely unknown, and therapy remains unchanged, aimed at controlling the heart rate and preventing systemic emboli with anticoagulation. Familial atrial fibrillation is more common than previously suspected. While atrial fibrillation is commonly associated with acquired heart disease, a significant proportion of individuals have early onset without other forms of heart disease, referred to as "lone" atrial fibrillators. It is also well recognized that atrial fibrillation occurs on a reversible or functional basis, without associated structural heart disease, such as with hyperthyroidism or of atrial fibrillation following surgery. It remains to be determined what percentage in these individuals is familial or due to a genetic predisposition. Mapping the locus for familial atrial fibrillation is the first step towards the identification of the gene. Isolation of the gene and subsequent identification of the responsible molecular genetic defect should provide a point of entry into the mechanism responsible for the familial form and the common acquired forms of the disease and eventually provide more effective therapy. We know that the ionic currents responsible for the action potential of the atrium is due to multiple channel proteins as is electrical conduction throughout the atria. Analogous to the ongoing genetic studies in patients with familial long QT syndrome, it is highly likely that defects in each of these channel proteins will be manifested in familial atrial fibrillation.